source
- Novartis forecasts modest 5% growth, bets on pipeline as Kisqali loses patentNovartis told investors it expects slower top‑line growth, narrowing its sales guidance to about 5% annual increase through 2031 as the breast‑cancer drug Kisqali faces patent expiry and price pres…
- Erasca claims stronger, better-tolerated pan-RAS cancer drug based on early Chinese dataErasca, a U.S. biotech, says it has identified a pan-RAS inhibitor in China that it believes is more potent and better tolerated than Revolution Medicines’ Rasonque. The claim rests on limited dat…